Suven Pharmaceuticals Ltd. (IN:COHANCE)
:COHANCE
Want to see IN:COHANCE full AI Analyst Report?
COHANCE Stock Chart & Stats
₹891.10
₹6.60(0.60%)
At close: 4:00 PM EST
₹891.10
₹6.60(0.60%)
Day’s Range― - ―
52-Week Range₹267.85 - ₹1,189.95
Previous CloseN/A
VolumeN/A
Average Volume (3M)116.47K
Market Cap
₹165.54B
Enterprise Value₹192.40B
Total Cash (Recent Filing)₹4.03B
Total Debt (Recent Filing)₹4.51B
Price to Earnings (P/E)92.3
Beta0.94
Next Earnings
May 28, 2026EPS Estimate
1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.97
Shares Outstanding382,567,140
10 Day Avg. Volume24,499
30 Day Avg. Volume116,469
Financial Highlights & Ratios
PEG Ratio-9.48
Price to Book (P/B)16.23
Price to Sales (P/S)23.00
P/FCF Ratio207.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.15
Revenue Forecast (FY)₹25.96B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained top-line expansion demonstrates growing demand for Suven's CDMO services and supports higher utilization of manufacturing capacity. Over a 2-6 month horizon this revenue momentum underpins reinvestment in capacity, strengthens customer credibility, and increases visibility into multi-stage program revenues.
Healthy Balance SheetLow leverage and a strong equity base provide financial flexibility to fund capex, weather project timing variability, and support selective M&A or process investments. This structural strength reduces refinancing and solvency risk and preserves capacity to serve regulated-market clients over time.
Specialized CDMO CapabilitiesTechnical expertise in complex small-molecule APIs and end-to-end CDMO services creates high entry barriers and sticky customer relationships. This specialization supports durable demand from innovator pharma and biotech clients and helps sustain margins and long-term revenue visibility as programs progress.
Bears Say
Weaker Free Cash FlowReduced free cash flow constrains the firm's ability to self-fund expansion, return capital, or absorb project timing delays. Over months this pressure can force prioritization of capex or working capital, elevating execution risk on scaling projects and slowing reinvestment into high-return manufacturing capacity.
Profitability / EPS ContractionMarked EPS decline signals margin pressure from higher operating costs, competitive pricing, or project mix shifts. Persistent earnings volatility undermines predictable cash generation and reduces flexibility to invest in high‑margin services or absorb regulatory/compliance costs, impacting sustainable returns.
Customer/program Concentration RiskRevenue depends on a limited number of customer programs progressing to commercial supply; delayed/terminated programs or client concentration can materially reduce volumes. This structural dependency raises step‑function revenue risk and makes forward visibility sensitive to individual customer decisions.
Suven Pharmaceuticals Ltd. News
COHANCE FAQ
What was Suven Pharmaceuticals Ltd.’s price range in the past 12 months?
Suven Pharmaceuticals Ltd. lowest stock price was ₹267.85 and its highest was ₹1189.95 in the past 12 months.
What is Suven Pharmaceuticals Ltd.’s market cap?
Suven Pharmaceuticals Ltd.’s market cap is ₹165.54B.
When is Suven Pharmaceuticals Ltd.’s upcoming earnings report date?
Suven Pharmaceuticals Ltd.’s upcoming earnings report date is May 28, 2026 which is in 29 days.
How were Suven Pharmaceuticals Ltd.’s earnings last quarter?
Suven Pharmaceuticals Ltd. released its earnings results on Feb 12, 2026. The company reported ₹0.975 earnings per share for the quarter, missing the consensus estimate of ₹2.693 by -₹1.718.
Is Suven Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Suven Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Suven Pharmaceuticals Ltd. pay dividends?
Suven Pharmaceuticals Ltd. pays a Notavailable dividend of ₹5 which represents an annual dividend yield of N/A. See more information on Suven Pharmaceuticals Ltd. dividends here
What is Suven Pharmaceuticals Ltd.’s EPS estimate?
Suven Pharmaceuticals Ltd.’s EPS estimate is 1.14.
How many shares outstanding does Suven Pharmaceuticals Ltd. have?
Suven Pharmaceuticals Ltd. has 382,567,140 shares outstanding.
What happened to Suven Pharmaceuticals Ltd.’s price movement after its last earnings report?
Suven Pharmaceuticals Ltd. reported an EPS of ₹0.975 in its last earnings report, missing expectations of ₹2.693. Following the earnings report the stock price went down -1.253%.
Which hedge fund is a major shareholder of Suven Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:COHANCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Suven Pharmaceuticals Ltd.
Cohance Lifesciences Limited is a Hyderabad-based pharmaceutical company specializing in contract development and manufacturing (CDMO) services, active pharmaceutical ingredients (APIs), and specialty chemicals. The company was formerly known as Suven Pharmaceuticals Limited and underwent a rebranding following its merger with Cohance Lifesciences, effective May 1, 2025.
Technical Analysis
Ajanta Pharma Limited
―
Biocon Limited
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―
Laurus Labs Ltd.
―